Condition: Muscle-Invasive Bladder Carcinoma · Sponsor: University Hospital, Ghent
Evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic bladder cancer patients and the treatment is adapted accordingly to improve overall survival.
This description comes directly from the study's public registry record.
Valerie Fonteyne, MD; PhD · +3293323015 · valerie.fonteyne@uzgent.be
Flor Verghote, MD · flor.verghote@uzgent.be
Always discuss trial participation with your own doctor first.
| Ghent University Hospital | Ghent, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04724928